Insilico Medicine launches sixth generation smart drug discovery laboratory

Insilico Medicine (“Insilico”), a clinical stage, artificial intelligence (AI) based drug discovery company, held a Life Star – a 6 launch ceremonyThe tenth Generation of intelligent drug discovery robotics lab – at BioBAY Suzhou Industrial Park on Dec. 29. The fully automated, AI-powered robotics laboratory performs target discovery, compound screening, precision medicine development, and translational research. The lab will allow Insilico to further accelerate end-to-end drug discovery and improve the success rate of its drug development while moving its new therapies through clinical trials.

High-throughput screening, automatic modules, and machine learning data generation are nothing new in the biomedical sector. So far, 5The tenth Generation botnet labs have achieved complete automation without human bias or influence, connecting multiple processes, and producing high-quality data that can be used for machine learning. The Insilico Medicine lab is taking this process a step further to integrate AI into decision making and deeply integrating AI with automation, robotics and biological capabilities to enable a new generation of intelligent robotic labs.

We hope to usher in a new era of biology labs. Insilico’s robotics lab contains an AI mind, robotic body, machine, and limbs of various complex robots. The AI ​​brain has been trained and validated by Insilico projects and learned from years of experience working with global pharmaceutical companies. It can carry out systematic learning based on the information provided, and assist in the decision-making on target discovery and setting. In the Intelligent Robotics Lab, the AI ​​brain will suggest potential targets and design experiments and automated workflows based on the experimental results.”

Alex Zavoronkov, Ph.D., founder and CEO of Insilico Medicine

The Intelligent Robotics Lab forms a closed loop by combining Pharma.AI (Insilico Medicine’s comprehensive AI platform for target discovery, new drug design, and clinical trial prediction) with fully automated biological trials functional modules.

Specifically, after the Pharma.AI PandaOmics target discovery platform predicts novel targets for specific diseases, the robotics lab will conduct early-stage drug discovery trials such as target validation, high-throughput compound screening, hit-to-lead optimization, and lead-to-clinical candidate confirmation ( PCC), compiler search. These biological experiments traditionally performed by humans will be achieved through six fully automated modules including sample management, quality control, compound management, automated cell culture, high-throughput screening, high-content cell imaging, and next-generation sequencing. All high-quality data produced by the Robotics Lab will complement and expand Insilico’s existing data resources to train and improve the AI ​​platform, powering Insilico’s biodata factory.

Feng Ren, chief scientific officer and co-CEO of Insilico Medicine, said, “Goal identification is the source of development of new drugs. One of the major challenges that the biomedical industry is currently facing is finding the right target. Now, Insilico Medicine proposes a comprehensive solution through its intelligent robotics laboratory. First, the laboratory assists in the efficient identification and validation of potential targets.Then it then evaluates and analyzes the activity and pharmacological potential of the designed compounds.In addition, it assists in the discovery of biomarkers and conducts studies on the mechanism of action through preclinical and translational research.The robotics laboratory has commenced work At Insilico Projects we look forward to providing this tool to advance the research of our academic and commercial partners.”

Founded in 2014, Insilico Medicine is one of the early players in drug discovery using artificial intelligence. It has built a powerful and powerful AI platform, Pharma.AI, to improve the speed, cost, and efficiency of drug discovery. Since 2021, Insilico has developed 9 preclinical candidates, including drug candidates with novel targets and structures discovered by AI, and drug candidates with desirable properties designed by AI targeting known targets. The projects are broadly spread across multiple disease areas including fibrosis, immuno-oncology, infections, and COVID-19.

Leave a Comment